Summary
Bromocriptine, an ergot-derivate with DA-receptor stimulating properties in vivo, produces long-lasting hypomotility in mice not accustomed to the motility cage and decreases brain DOPAC and HVA without affecting brain DA. These effects are obtained with doses 25 times lower than those which produce hypermotility. The decrease of brain DOPAC is correlated to the hypomotility both on a dose- and on a time-basis.
Potent neuroleptics as pimozide, benzperidol and droperidol, which are considered to be fairly specific DA-receptor blockers, antagonize the hypomotility and the decrease of brain DOPAC produced by bromocriptine. These effects are obtained with very low doses (0.05–0.3 mg/kg) of neuroleptics which per se do not affect motility or brain DOPAC. The maximal decrease of brain DOPAC and HVA produced by bromocriptine is similar to that produced by apomorphine and the combination of these drugs does not result in a further decrease of brain DOPAC or HVA. On the basis of these results it is postulated that bromocriptine decreases brain DA-turnover and produces hypomotility by acting on “regulatory” DA-receptors different from the post-synaptic ones of the “terminal” dopaminergic areas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bunney, B. S., Aghajanian, G. K.: Evidence for drug actions on both pre- and postsynaptic catecholamine receptors in the CNS. In: Pre- and post-synaptic receptors (Usdin, E., and Bunney, W. E., Jr., eds.), pp. 89–122. New York: Marcel Dekker 1975
Burt, D. R., Creese, J., Snyder, S. H.: Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Mol. Pharmacol. 12, 631–638 (1976)
Calne, D. B., Leigh, P. N., Teychenne, P. F., Bamji, A. N., Greenace, J. K.: Treatment of parkinsonism with bromocriptin. Lancet 7, 1355–1356 (1974a)
Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenace, J. K., Petrie, A.: Bromocriptine in parkinsonism. Br. Med. J. 4, 442–444 (1974b)
Carlsson, A.: Receptor-mediated control of dopamine metabolism. In: Pre- and postsynaptic receptor (Usdin, E., and Bunney, W. E., Jr., eds.), pp. 49–65. New York: Matcel Dekker Inc., 1975
Corrodi, H., Fuxe, K., Hokfelt, T., Lidbrink, P., Ungerstedt, U.: Effects of ergot drugs on central neurons: evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol. 25, 409–410 (1973)
Creese, I., Burt, D. R., Snyder, S. H.: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481–483 (1976)
Cristiansen, J., Squires, R. F.: Anagonistic effects of apomorphine and haloperidol on rat striatal synaptosomal tyrosine hydroxylase. J. Pharm. Pharmacol. 26, 367–369 (1974a)
Cristiansen, J., Squires, R. F.: Antagonistic effects of neuroleptics and apomorphine on synaptosomal tyrosine hydroxylase in vitro. J. Pharm. Pharmacol. 26, 742–743 (1974b)
Del Pozo, E., Varga, L., Wyss, H., Tolis, G., Friesen, H., Wenner, R., Vetter, L., Uettwiler, A.: Clinical and hormonal response to bromocriptin (CB-154) in the galactorrhea syndromes. J. Clin. Endocr. 39, 18–26 (1974)
Di Chiara, G., Balakleevsky, A., Porceddu, M. L., Tagliamonte, A., Gessa, G. L.: Inhibition by apomorphine of dopamine deamination in the rat brain. J. Neurochem. 23, 1105–1108 (1974)
Di Chiara, G., Porceddu, M. L., Vargiu, L., Argiolas, A., Gessa, G. L.: Evidence for dopamine receptors in the mouse brain mediating sedation. Nature 264, 564–567 (1976)
Di Chiara, G., Mereu, G. P., Vargiu, L., Porceddu, M. L., Mulas, A., Trabucchi, M., Spano, P. F.: Evidence for existence of regulatory dopamine-receptors in the substantia nigra. In: Advances in biochemical psychopharmacology (Costa, E., and Gessa, G. L., eds.), vol. 16, pp. 477–481. New York: Raven Press 1977a
Di Chiara, G., Porceddu, M. L., Fratta, W., Gessa, G. L.: Post-synaptic receptors are not essential for dopaminergic feed-back regulation. Nature 267, 270–272 (1977b)
Di Chiara, G., Porceddu, M. L., Spano, P. F., Gessa, G. L.: Haloperisol increases and apomorphine decreases striatal dopamine metabolism after destruction of striatal dopamine-sensitive adenylate-cyclase by kainic acid. Brain Res. 130, 374–382 (1977c)
Di Chiara, G., Gessa, G. L.: Pharmacology and neurochemistry of apomorphine. Adv. Pharmacol Chemother. 15, 1977 (in press)
Farnebo, L. O., Hamberger, B.: Drug-induced changes in the release of 3H-monoamines from field stimulated rat brain slices. Acta Physiol. Scand., Suppl. 371, 35–44 (1971)
Fluckiger, E.: Drugs and the control of prolactin secretion. In: Prolactin and carcinogenesis (Boyns, A. R., and Griffiths, K., eds.). Cardiff: Alpha Omega Alpha Publishing 1972
Fuxe, K., Corrodi, H., Hokfelt, T., Lidbrink, P., Ungerstedt, U.: Ergocornine and 2-Br-x-ergocryptine. Evidence for prolonged dopamine receptor stimulation. Med. Biol. 52, 121–126 (1974)
Groves, P. M., Wilson, C. J., Young, S. J., Rebec, G. V.: Sell-inhibition by dopaminergic neurons. Science 190, 522–529 (1975)
Iversen, L. L., Rogawski, M. A., Miller, R. J.: Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum. Mol. Pharmacol. 12, 251–262 (1976)
Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L.: Is it possible to predict the clinical effects of neuroleptic drugs (Major Tranquilizer) from animal data. Arzneim.-Forsch. 15, 104–118 (1965)
Johnson, A. M., Vigouret, J. M., Loew, D. M.: Central dopaminergic actions of ergotoxine alkaloids and some derivatives. Experientia 29, 763–765 (1973)
Johnson, A. M., Loew, D. M., Vigouret, J. M.: Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and l-dopa. Br. J. Pharmacol. 56, 59–68 (1976)
Kebabian, J. W., Saavedra, J. M.: Dopamine-sensitive adenylate cyclase occurs in a region of substantia nigra containing dopaminergic dendrites. Science 193, 683–685 (1976)
Kehr, W., Carlsson, A., Lindqvist, M., Magnusson, T., Atack, C.: Evidence of a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J. Pharm. Pharmacol. 24, 744–747 (1972)
Kelly, P. H., Seviour, P. W., Iversen, S. D.: Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94, 507–522 (1975)
Murphy, G. F., Robinson, D., Sharman, D. F.: The effect of tropolone on the formation of 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the brain of the mouse. Br. J. Pharmacol. 36, 107–115 (1969)
Phillipson, O. T., Horn, A. S.: Substantia nigra of the rat contains a dopamine sensitive adenylate cyclase. Nature 261, 418–420 (1976)
Premont, J., Thierry, A. M., Tassin, J. P., Glowinski, J., Blanc, G., Bockaert, J.: Is the dopamine sensitive adenylate cyclase in the rat substantia nigra coupled with “autoreceptors”? FEBS Lett. 68, 99–104 (1976)
Roberts, D. C. S., Zis, A. P., Fibiger, H. C.: Ascending catecholamine pathways and amphetamine-induced locomotor activity: importance of dopamine and apparent non-involvement of norepinephrine. Brain Res. 93, 441–446 (1975)
Roth, R. H., Murrin, L. C., Walters, J. R.: Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid. Eur. J. Pharmacol. 36, 163–171 (1976)
Spano, P. F., Di Chiara, G., Tonon, G., Trabucchi, M.: A dopaminesensitive adenylate-cyclase in rat substantia nigra. J. Neurochem. 27, 1565–1568 (1976)
Spano, P. F., Trabucchi, M., Di Chiara, G.: Localization of nigral DA-sensitive adenylate cyclase on neurons originating from the corpus striatum. Science 196, 1343–1344 (1977)
Stefenini, E., Fadda, F., Medda, L., Gessa, G. L.: Selective inhibition of serotonin uptake by trazodone, a new antidepressant agent. Life Sci. 18, 1459–1466 (1976)
Strömbom, U.: Catccholamine receptor agonists. Effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 292, 167–176 (1976)
Thorner, M. O., Chait, A., Aitken, M., Benker, G., Bloom, S. R., Mortimer, C. H., Sanders, P., Stuart Mason, A., Besser, G. M.: Bromocriptine treatment of acromegaly. Br. Med. J. 1, 299–303 (1975)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Di Chiara, G., Porceddu, M.L., Vargiu, L. et al. Evidence for selective and long-lasting stimulation of “regulatory” dopamine-receptors by bromocriptine (CB 154). Naunyn-Schmiedeberg's Arch. Pharmacol. 300, 239–245 (1977). https://doi.org/10.1007/BF00500966
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00500966